mRCC
Genomic Markers Can Predict Response to Targeted Rx in mRCC
Several mutational markers can indicate responsiveness to vascular endothelial growth factor-targeted therapy in ...
NOVEMBER 29, 2017
ctDNA Testing Finds Extensive Genomic Alterations in mRCC
Using ctDNA profiling, investigators detected genomic alterations GAs in nearly 80 of patients with mRCC as well as ...
NOVEMBER 3, 2017
Study Supports Nivo-Ipi Combo Over Monotherapy for mRCC
The combination of nivolumab and ipilimumab may be more effective for treating metastatic renal cell carcinoma ...
AUGUST 17, 2017
Long-Term Outcomes Better in mRCC Pts With CR to VEGF Inhibitors
Patients with metastatic renal cell carcinoma (mRCC) who experience complete response (CR) after two years of ...
AUGUST 17, 2017
Consider Neoadjuvant, Adjuvant Targeted Therapy for RCC
Neoadjuvant targeted therapy for renal cell carcinoma is less toxic than adjuvant targeted therapy, but both should ...
AUGUST 9, 2017
Alternate Sunitinib Schedule Is Feasible for mRCC
Although an alternate schedule of sunitinib in patients with mRCC failed to reduce grade 3 or higher toxicity ...
JULY 18, 2017
Combination Therapy Shows Promise in mRCC
The combination of atezolizumab (Tecentriq, Genentech) and bevacizumab (Avastin, Genentech) appears to be a ...
JUNE 28, 2017
Individualized Sunitinib Dosing Provides Better Fit
Customized dosing of first-line sunitinib is safe and feasible, providing better response rates and survival in ...
JUNE 27, 2017
mRCC Control Seen After Immunotherapy Is Stopped
Orlando, Fla.—Patients with mRCC who respond to programmed death 1/programmed death ligand 1 checkpoint ...
MAY 9, 2017
Some Pts Benefit From Sunitinib Dose Escalation
Patients with mRCC who have disease progression on the standard dose of sunitinib may experience response with a ...
MARCH 7, 2017
Severe Systemic Inflammation Heralds Poor mRCC Outcomes
Outcomes in mRCC are poor if severe systemic inflammation (SSI) is present, according to a study presented at ASCO ...
MARCH 7, 2017
Response to Cytoreductive Nephrectomy May Predict Survival
A patient’s response to cytoreductive nephrectomy three months later may be a prognostic indicator of ...
FEBRUARY 15, 2017